SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RVMD

Revolution Medicines, Inc. (NASDAQ:RVMD)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$161.20+$1.77 (+1.11%)
 
Market cap
$34.9B
Insider Score
Analyst consensus
Listed since
Feb 13, 2020
Website
Market Cap$34.87B+127.5%
Revenue (ttm)n/a
Net Incomen/a-94.6%
EPSn/a-76.6%
Shares Out216.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,739,343
Open$161.61
Previous Close$159.43
Day's Range$160.24 - $169.51
52-Week Range$69.50 - $224.31
Beta1.43
AnalystsBuy
Price Target$258.28(+60.22%)
Earnings Daten/a

About RVMD

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Address
700 Saginaw Drive, Redwood City, CA, 94063, US
Market Cap
34.87 billion
Employees
883
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$11.94M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
13 Buy0 Hold0 SellAvg target $221.77 (+37.6%)

13 firms rating RVMD in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+1.11%
5 Days
-6.28%
1 Month
-17.03%
6 Months
+4.86%
1 Year
+127.46%

$RVMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RVMD holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RVMD's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RVMD Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RVMD patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RVMD from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RVMD

VTIVanguard Morningstar Total Stock Market ETF$977.25M
VBVanguard Morningstar Small-Cap ETF$873.35M
VBKVanguard Morningstar Small-Cap Growth ETF$488.79M
VXFVanguard Extended Market ETF$441.79M
IBBiShares Biotechnology ETF$239.01M
IWPiShares Russell Mid-Cap Growth ETF$171.93M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RVMD’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: EU regulatory approval for lead pancreatic cancer drug, strong clinical data, and competitive positioning offset valuation concerns.

Recent Insider Activity

Buys
0
Sells
20
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-34.0 since Aug 26
0255075100Aug 26 — Insider Score 34.0Aug 27 — Insider Score 34.0Aug 28 — Insider Score 35.0Aug 29 — Insider Score 35.0Aug 30 — Insider Score 35.0Aug 31 — Insider Score 35.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 24.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 26Sep 14Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CANCTema Oncology ETF5.34%
HLTHTema Healthcare AI ETF5.05%
BBHVanEck Biotech ETF3.52%
ADPVAdaptiv Select ETF3.47%
PTHInvesco Dorsey Wright Healthcare Momentum ETF3.39%
IDNAiShares Genomics Immunology and Healthcare ETF3.38%
HRTSTema Heart & Health ETF3.16%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF3.06%
MEDIHarbor Health Care ETF (MEDI)2.79%
IBBQInvesco Nasdaq Biotechnology ETF2.43%
DRKYVistaShares Target 15 DRUKMacro Distribution ETF2.39%
IBBiShares Biotechnology ETF2.35%

Weight is the stock’s share of each fund’s holdings.